The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.

The invention features probiotic bacteria expressing Clostridium difficile SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.

The invention relates to compositions for preventing or delaying the onset of hepatocellular cancer. The compositions of the invention may comprise short chain fatty acids. The compositions of the invention may also comprise probiotic bacteria. The compositions of the invention include compositions for preventing or delaying the onset of hepatocellular cancer by treating or preventing liver inflammation, liver disease, and precancerous lesions.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

The present invention relates generally to the field of compositions comprising myo- inositol for use in the prevention of post partum haemorrhage (PPH) and disorders and/or conditions linked thereto. The composition may be a nutritional composition, for example a maternal nutrition composition. The composition may be specifically designed to provide optimized nutrition to a woman desiring to get pregnant, to a pregnant woman or to a woman who gave birth.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

A method useful for providing a phytonutrient to a subject via mediation of the subject’s microbiome is disclosed. The method includes administering a phytofunctional composition to a subject change the phytonutrient producer status of the subject. The method may also include identifying a phytonutrient producer status of the subject by assessing a level of at least one of a preselected phytonutrient and a preselected phytonutrient precursor compound within the subject. A phytofunctional composition useful in the method is also disclosed, and comprises a phytonutrient precursor compound and an active agent. The active agent comprises a probiotic and/or a prebiotic, and is adapted to mediate production of the preselected phytonutrient in the gastrointestinal tract of the subject, thereby changing the phytonutrient producer status of the subject.

The invention provide a mix or a nutritional compostion comprising a probiotic Lactobacillus Fermentum CECT-5716 and a n-3 fatty acid selected from the group consisting of docosahexaenoic acid (DHA) and 18:3 n-3 octadecatrienoic acid (alpha-linolenic acid); and optional a further nutrient or mineral selected from the group consisting of iron, manganese and magnesium, or combination of two of more thereof; for use in treating or preventing mastitis in a subject, preferably a pregnant or lactating woman.